Neurology · Clinical trials
Restless Legs Syndrome Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About restless legs syndrome — and why its trials are hard
Restless legs syndrome (RLS, Willis-Ekbom disease) is a common sensorimotor disorder causing an urge to move the legs, usually with uncomfortable sensations, that worsens at rest and in the evening/night and is relieved by movement, frequently disrupting sleep. Pathophysiology centers on brain iron deficiency and dopaminergic dysfunction. Historically, dopamine agonists were first-line and gained FDA approvals: ropinirole (Requip), pramipexole (Mirapex), and the rotigotine transdermal patch (Neupro). However, long-term dopaminergic therapy is now limited by augmentation, a paradoxical worsening and spread of symptoms that has shifted guidelines away from dopamine agonists as preferred first-line agents. Alpha-2-delta ligands are increasingly favored: gabapentin enacarbil (Horizant) is FDA-approved for moderate-to-severe RLS, and gabapentin/pregabalin are used off-label. Iron repletion (oral or IV) is foundational, especially when ferritin is low. Opioids are reserved for refractory cases. Symptom severity is standardly measured with the International RLS Study Group Rating Scale (IRLS).
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Ropinirole (Requip) | 2005 | Moderate-to-severe primary RLS (first drug FDA-approved for RLS) | Randomized double-blind placebo-controlled trials (TREAT RLS program) | Change in IRLS total score and CGI-I responder rate | Significant IRLS reduction versus placebo; higher responder rates, offset long-term by augmentation risk |
| Pramipexole (Mirapex) | 2006 | Moderate-to-severe primary RLS | Randomized double-blind placebo-controlled trials | Change in IRLS total score | Significant IRLS improvement over placebo; also subject to augmentation with chronic use |
| Rotigotine (transdermal patch) (Neupro) | 2012 (RLS indication in the US) | Moderate-to-severe primary RLS (continuous 24-hour delivery) | Randomized double-blind placebo-controlled trials | Change in IRLS total score | Significant IRLS reduction; steady delivery may reduce but not eliminate augmentation |
| Gabapentin enacarbil (Horizant) | 2011 | Moderate-to-severe primary RLS (alpha-2-delta ligand; non-dopaminergic) | Randomized double-blind placebo-controlled trials | Change in IRLS total score and CGI-I responder rate | Significant IRLS improvement over placebo; not associated with augmentation, a key advantage |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in restless legs syndrome development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Dopamine agonists (class-level limitation) — Long-term/observational and extension studies | Augmentation — progressive worsening, earlier onset, and spread of symptoms — undermines chronic use | Chronic dopaminergic stimulation drives augmentation, prompting guideline shift toward alpha-2-delta ligands as preferred first-line |
Choosing the right endpoint
Primary endpoints that matter in restless legs syndrome trials
- IRLS (International RLS Study Group Rating Scale) — Primary severity endpoint across RLS trials
- CGI-I (Clinical Global Impression - Improvement) — Responder-rate measure of overall improvement
- Periodic limb movements index (polysomnography) — Objective sleep-lab measure of leg movements during sleep
- Sleep quality / MOS sleep measures — Captures the major functional burden of RLS on sleep
- Augmentation assessment — Critical long-term safety endpoint specific to dopaminergic therapy
How iNGENū runs restless legs syndrome trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Restless Legs Syndrome clinical trials — FAQs
What is augmentation in RLS?
Which drugs are FDA-approved for RLS?
How does iron fit into RLS treatment?
Ready to discuss your restless legs syndrome trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal